Doximity (DOCS) Stock Analysis & AI Equity Report
Doximity (DOCS) overview
Doximity (DOCS) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 645m and operating profit of USD 215m; the year-end share price was 23.30 USD and market capitalisation was USD 4,265m. Doximity is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Doximity's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Doximity
Doximity operates a professional technology platform for physicians and other medical professionals, with tools for collaboration, medical news, career management, scheduling, virtual visits and clinical workflows. Its customers, primarily pharmaceutical manufacturers and health systems, use marketing and digital recruiting solutions. Workflow offerings include telehealth, on-call scheduling, digital fax and clinical AI tools designed to support clinicians and patient care.
Generate the Doximity report
Doximity is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Doximity and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Doximity
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.